Image for Gradientech and Momentum Bioscience in continued collaboration
IR Press releasesNews 2024-07-04

Gradientech and Momentum Bioscience in continued collaboration

The diagnostics company Gradientech today announces the continued collaboration with Oxford-based Momentum Bioscience Ltd in the ground-breaking project to demonstrate the potential for a next-generation diagnostic workflow for patients with sepsis, together providing the fastest solution to precise phenotypic AST results directly from blood.

Momentum Bioscience is developing the SepsiSTAT® technology allowing isolation and separation of bacteria directly from blood. By combining the enrichment technology from Momentum Bioscience with the CE marked QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) by Gradientech, AST in a few hours directly from blood is demonstrated. Results from earlier collaborations between the two companies were presented during ECCMID and ASM Microbe last year, with the project now being extended to include the latest development of automation and bacterial enrichment at Momentum Bioscience.  

“Blood culture-free workflows for bacterial identification and AST are a significant advancement for rapid and accurate guidance of antibiotic treatment. Newer rapid AST systems such as Gradientech’s QuickMIC are an excellent complement to our blood-culture-free direct-from-blood technology,” says Sumi Thaker, CEO at Momentum Bioscience.

“We are excited to continue our collaboration with Momentum Bioscience. Combining a solution like the SepsiSTAT approach with our QuickMIC system for ultra-rapid AST shows significantly reduced turnaround time and could lessen the reliance on specialised microbiology laboratories in the future, potentially moving sepsis diagnostics closer to the sepsis patients in need,” says Sara Thorslund, co-founder and CEO at Gradientech.

The QuickMIC system’s ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.

For further information, please contact:

Sara Thorslund, PhD, CEO  
Tel: +46 (0)736 29 35 80  


Sumi Thaker, CEO

Tel: +44 (0)29 2167 7910

About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden.
Visit for more information.


About Momentum Bioscience

Driven by unmet needs when managing patients with sepsis, the team at Momentum Bioscience are creating innovative approaches that help healthcare professionals act faster and smarter when diagnosing bloodstream infection and targeting antimicrobial treatments to save lives.  Momentum Bioscience are a proud recipient of a grant from the European Innovation Council’s Accelerator competition (2023). 
Visit for more information.